Tandem transplantation in lymphoma

Bone Marrow Transplantation
K P PapadopoulosC S Hesdorffer

Abstract

The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U VitoloV Meneghini
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 2, 1997·Bone Marrow Transplantation·M de LimaR E Champlin
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M StoppaD Maraninchi
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusM M Horowitz
Jan 13, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I F KhouriR Champlin
Mar 21, 2000·Bone Marrow Transplantation·A M CarellaR Storb
Nov 9, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L J JohnstonS J Horning
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseUNKNOWN Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee
Apr 25, 2001·Bone Marrow Transplantation·I W Flinn, H M Lazarus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.